Compare Amphastar Pharmaceuticals Inc (AMPH) vs Exxon Mobil Corporation (XOM) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

ExxonMobil (XOM) trades at $138.83, up 1.06% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $1.16, beating estimates, while revenue declined to $323.91 billion in 2025. Analyst consensus is mixed with 42.59% buy ratings and a $169.30 price target. Recent news highlights Exxon's Permian Basin advantages and warnings of potential oil price spikes to $160 per barrel amid Middle East tensions.

XOM offers value with a P/E of 23.38 and strong cash flow, but faces headwinds from declining revenue and net income margins. Investment appeal hinges on oil price stability and execution in low-breakeven assets like the Permian Basin. Risks include volatile energy markets and geopolitical tensions affecting global supply.